Publications

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern

Foundational Tools for Building a New Bioeconomy

Microfluidic chip-based single-cell cloning to accelerate biologic production timelines

High-throughput optofluidic screening for improved microbial cell factories via real-time micron-scale productivity monitoring

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants

Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of ex vivo Expanded Human Hematopoietic Stem Cells

A singular view of COVID-19

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Assuring Clonality on the Beacon Digital Cell Line Development Platform

Nanoscale Integration of Single Cell Biologics Discovery Processes Using Optofluidic Manipulation and Monitoring

Rapid single B cell antibody discovery using nanopens and structured light

Multiparameter cell characterization using nanofluidic technology facilitates real-time phenotypic and genotypic elucidation of intratumor heterogeneity

A Novel Mammalian Cell Line Development Platform Utilizing Nanofluidics and OptoElectro Positioning Technology

Light-Activated Cell Identification and Sorting (LACIS): A New Method to Identify and Select Edited Clones on a Microfluidic Device

Customer Videos

Accelerating Cell Culture Development through Practical Application of Innovative Technologies

Thermo Fisher Scientific on developing a faster, more efficient, and regulatory ready cell line and cell culture.

Get to IND Faster: Accelerated & High Performance Cell Line Development

Samsung Biologics on how to expedite development timeline and obtain IND clearance and starting phase 1 study faster.

Leveraging Innovative Technologies to Accelerate Biologics Development

Thermo Fisher Scientific on how to get more molecules to the clinic faster.

Characterizing T Cell Functionality on the Berkeley Lights Lightning Platform

Medical College of Wisconsin on how to determine the phenotypic and functional characteristics of cells in real time, isolate specific cells of interest, and link the genomic profiles of these same cells using downstream assays.

Looking to the Future: What’s next in Antibody Therapeutics

Abveris, Genovac, and Berkeley Lights on the evolving landscape of antibody therapeutics, the technologies they have turned to to address today’s complex targets, and how they are preparing for tomorrow’s challenges.

Tackle Difficult Targets by Accessing Broad B Cell Diversity

Genovac on how to find 10 times more lead candidates than hybridoma in just days.

A Beacon for Rapid Antibody Discovery against Difficult Targets

Genovac and Berkeley Lights on how to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.

Every Day Matters – Optimizing COVID-19 Therapies for Manufacturing

Nobel Laureate, Dr. James Rothman, Amgen, Catalent-Biologics, and University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.

Rapid Discovery of Functional Antibodies for SARS-CoV-2 Using the Beacon System

Vanderbilt University Medical Center on how to rapidly discover hundres of unique antibodies against SARS-CoV-2.

How Pediatric Immune Systems Empower Cancer Immunotherapy

Children’s Hospital of Philadelphia shares insight into why children’s T cells help CAR-T cells succeed and how to develop more efficacious therapies.

Accelerating Antibody Discovery in the Modern Therapeutic Landscape

Abveris on how to accelerate the development of next-generation antibody therapeutics.